Medically reviewed by Kelly Wood, MD The endocrine system is made of glands that produce hormones (chemical messengers), ...

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Helene Lindfors, Ph.D. Student at the Endocrine Surgery research group, the Department of Molecular Medicine and Surgery, ...

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

A new research paper was published by Aging (Aging-US) on March 7, 2025, titled “Accelerated aging associated with cancer ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...